Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 499-503

  Lee, Je Hwan ^a   Lee, Kyoo Hyung ^a   Lee, Jung Hee ^a   Kim, Dae Young ^a   Kim, Sung Han ^a   Lim, Sung Nam ^a   Kim, Sung Doo ^a   Choi, Yunsuk ^a   Lee, Sang Min ^b   Lee, Won Sik ^b   Choi, Moon Young ^b   Joo, Young Don ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Antibiotic prophylaxis; Cytopenia; Decitabine; Febrile episode; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACICLOVIR; CEFIXIME; CIPROFLOXACIN; ITRACONAZOLE; LEVOFLOXACIN; QUINOLONE DERIVATIVE;

ACUTE APPENDICITIS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIMETABOLITES, ANTINEOPLASTIC; APPENDICITIS; AZACITIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; FLUOROQUINOLONES; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952361362     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.006     Document Type: Article

References (36)

1. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
2. Mund C., Hackanson B., Stresemann C., Lubbert M., Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005, 65:7086-7090.
3. Saba H.I. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manage 2007, 3:807-817.
4. Leone G., Teofili L., Voso M.T., Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002, 87:1324-1341.
5. Pinto A., Zagonel V. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993, 7(Suppl. 1):51-60.
6. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
7. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
8. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
9. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956-962.
10. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
11. Schimpff S.C. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986, 80:13-20.
12. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
13. Pascoe J., Steven N. Antibiotics for the prevention of febrile neutropenia. Curr Opin Hematol 2009, 16:48-52.
14. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
15. Segal B.H., Freifeld A.G., Baden L.R., Brown A.E., Casper C., Dubberke E., et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008, 6:122-174.
16. Jain N., Mattiuzzi G.N., Cortes J., Cassat J., Garcia-Manero G., Ravandi-Kashani F., et al. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline "targeted therapy" (Abstract No 2858). Blood 2007, 110:841a.
17. Mattiuzzi G.N., Cortes J.E., Faderl S., Cabanillas M.E., Giles F.J., O'Brien S., et al. Patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) treated with targeted therapy may benefit from prophylactic measures against infections (Abstract No 4483). Blood 2006, 108:199b.
18. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
19. Hammond S.P., Baden L.R. Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 2008, 49:183-193.
20. Leibovici L., Paul M., Cullen M., Bucaneve G., Gafter-Gvili A., Fraser A., et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006, 107:1743-1751.
21. Lo N., Cullen M. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 2006, 24:120-125.
22. Bucaneve G., Micozzi A., Menichetti F., Martino P., Dionisi M.S., Martinelli G., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987.
23. Cullen M., Steven N., Billingham L., Gaunt C., Hastings M., Simmonds P., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998.
24. Engels E.A., Lau J., Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998, 16:1179-1187.
25. Gafter-Gvili A., Fraser A., Paul M., Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995.
26. Reuter S., Kern W.V., Sigge A., Dohner H., Marre R., Kern P., et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005, 40:1087-1093.
27. Cullen M.H., Billingham L.J., Gaunt C.H., Steven N.M. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007, 25:4821-4828.
28. Imran H., Tleyjeh I.M., Arndt C.A., Baddour L.M., Erwin P.J., Tsigrelis C., et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008, 27:53-63.
29. Cruciani M., Malena M., Bosco O., Nardi S., Serpelloni G., Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003, 21:4127-4137.
30. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
31. Muller-Berndorff H., Haas P.S., Kunzmann R., Schulte-Monting J., Lubbert M. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol 2006, 85:502-513.
32. Navarro I., Ruiz M.A., Cabello A., Collado R., Ferrer R., Hueso J., et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res 2006, 30:971-977.
33. Lee J.H., Shin Y.R., Lee J.S., Kim W.K., Chi H.S., Park C.J., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003, 17:305-313.
34. Matsuda A., Germing U., Jinnai I., Misumi M., Kuendgen A., Knipp S., et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005, 106:2633-2640.
35. Wang X.Q., Ryder J., Gross S.A., Lin G., Irons R.D. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. Int J Hematol 2009, 90:361-369.
36. Toyama K., Ohyashiki K., Yoshida Y., Abe T., Asano S., Hirai H., et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993, 7:499-508.